Aptose Biosciences Inc APTO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if APTO is a good fit for your portfolio.
News
-
Aptose Reports Results for the Fourth Quarter and Full Year 2023
-
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
-
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
-
Thinking about buying stock in Cipher Mining, SoundHound AI, Cellectar Biosciences, Bitdeer Technologies, or Aptose Biosciences?
-
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
Trading Information
- Previous Close Price
- $1.26
- Day Range
- $1.25–1.29
- 52-Week Range
- $1.20–8.70
- Bid/Ask
- $1.19 / $1.34
- Market Cap
- $19.96 Mil
- Volume/Avg
- 34,780 / 83,462
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 36
- Website
- https://www.aptose.com
Valuation
|
Metric
|
APTO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
APTO
|
|---|---|
Quick Ratio | 0.61 |
Current Ratio | 0.78 |
Interest Coverage | — |
Quick Ratio
APTO
Profitability
|
Metric
|
APTO
|
|---|---|
Return on Assets (Normalized) | −157.68% |
Return on Equity (Normalized) | −288.57% |
Return on Invested Capital (Normalized) | −275.95% |
Return on Assets
APTO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lpsvppnpk | Hqkjm | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hglrnwng | Bphfp | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vsbczvy | Gwrwz | $98.1 Bil | |
MRNA
| Moderna Inc | Njfyxsdp | Nrxxq | $39.1 Bil | |
ARGX
| argenx SE ADR | Hvgxcltbg | Xnf | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Sqtthxmxx | Mrdxr | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Cjqnlympx | Wgmznbs | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mrrgwwvj | Lrftp | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rbgrqxhhlz | Mcvrsm | $12.5 Bil | |
INCY
| Incyte Corp | Jkwllhfk | Pgdbtn | $11.9 Bil |